171 related articles for article (PubMed ID: 32552088)
1. An overview of current and emerging diagnostic, staging and prognostic markers for prostate cancer.
Brönimann S; Pradere B; Karakiewicz P; Abufaraj M; Briganti A; Shariat SF
Expert Rev Mol Diagn; 2020 Aug; 20(8):841-850. PubMed ID: 32552088
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers in prostate cancer - Current clinical utility and future perspectives.
Kretschmer A; Tilki D
Crit Rev Oncol Hematol; 2017 Dec; 120():180-193. PubMed ID: 29198331
[TBL] [Abstract][Full Text] [Related]
3. Genomic Markers in Prostate Cancer Decision Making.
Cucchiara V; Cooperberg MR; Dall'Era M; Lin DW; Montorsi F; Schalken JA; Evans CP
Eur Urol; 2018 Apr; 73(4):572-582. PubMed ID: 29129398
[TBL] [Abstract][Full Text] [Related]
4. Tumour markers in prostate cancer: The post-prostate-specific antigen era.
Garrido MM; Bernardino RM; Marta JC; Holdenrieder S; Guimarães JT
Ann Clin Biochem; 2022 Jan; 59(1):46-58. PubMed ID: 34463154
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of New Tests and Interventions for Prostate Cancer Management: A Systematic Review.
Olleik G; Kassouf W; Aprikian A; Hu J; Vanhuyse M; Cury F; Peacock S; Bonnevier E; Palenius E; Dragomir A
J Natl Compr Canc Netw; 2018 Nov; 16(11):1340-1351. PubMed ID: 30442734
[No Abstract] [Full Text] [Related]
6. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions.
Hendriks RJ; van Oort IM; Schalken JA
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):12-19. PubMed ID: 27922627
[TBL] [Abstract][Full Text] [Related]
7. A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges.
Kohaar I; Petrovics G; Srivastava S
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013716
[TBL] [Abstract][Full Text] [Related]
8. Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics.
Moschini M; Spahn M; Mattei A; Cheville J; Karnes RJ
BMC Med; 2016 Apr; 14():67. PubMed ID: 27044421
[TBL] [Abstract][Full Text] [Related]
9. Are localized prostate cancer biomarkers useful in the clinical practice?
Carneiro A; Priante Kayano P; Gomes Barbosa ÁR; Langer Wroclawski M; Ko Chen C; Cavlini GC; Reche GJ; Sanchez-Salas R; Tobias-Machado M; Sowalsky AG; Bianco B
Tumour Biol; 2018 Sep; 40(9):1010428318799255. PubMed ID: 30204063
[TBL] [Abstract][Full Text] [Related]
10. Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline.
Eggener SE; Rumble RB; Armstrong AJ; Morgan TM; Crispino T; Cornford P; van der Kwast T; Grignon DJ; Rai AJ; Agarwal N; Klein EA; Den RB; Beltran H
J Clin Oncol; 2020 May; 38(13):1474-1494. PubMed ID: 31829902
[TBL] [Abstract][Full Text] [Related]
11. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility of emerging biomarkers in prostate cancer liquid biopsies.
Boerrigter E; Groen LN; Van Erp NP; Verhaegh GW; Schalken JA
Expert Rev Mol Diagn; 2020 Feb; 20(2):219-230. PubMed ID: 31577907
[No Abstract] [Full Text] [Related]
13. Novel Diagnostic Biomarkers of Prostate Cancer: An Update.
Anceschi U; Tuderti G; Lugnani F; Biava PM; Malossini G; Luciani L; Cai T; Marsiliani D; Filianoti A; Mattevi D; Costantini M; Misuraca L; Simone G
Curr Med Chem; 2019; 26(6):1045-1058. PubMed ID: 30215331
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers for prostate cancer: prostate-specific antigen and beyond.
Duffy MJ
Clin Chem Lab Med; 2020 Feb; 58(3):326-339. PubMed ID: 31714881
[TBL] [Abstract][Full Text] [Related]
15. A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection.
Hendriks RJ; van der Leest MMG; Dijkstra S; Barentsz JO; Van Criekinge W; Hulsbergen-van de Kaa CA; Schalken JA; Mulders PFA; van Oort IM
Prostate; 2017 Oct; 77(14):1401-1407. PubMed ID: 28853167
[TBL] [Abstract][Full Text] [Related]
16. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
17. Novel biomarkers and genomic tests in prostate cancer: a critical analysis.
Falzarano SM; Ferro M; Bollito E; Klein EA; Carrieri G; Magi-Galluzzi C
Minerva Urol Nefrol; 2015 Sep; 67(3):211-31. PubMed ID: 26054411
[TBL] [Abstract][Full Text] [Related]
18. An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer.
Mollica V; Di Nunno V; Santoni M; Cimadamore A; Scarpelli M; Lopez-Beltran A; Cheng L; Mariani C; Battelli N; Montironi R; Massari F
Expert Rev Mol Diagn; 2020 Feb; 20(2):207-217. PubMed ID: 31640441
[No Abstract] [Full Text] [Related]
19. Prostate Cancer Markers.
Gadzinski AJ; Cooperberg MR
Cancer Treat Res; 2018; 175():55-86. PubMed ID: 30168117
[TBL] [Abstract][Full Text] [Related]
20. Noncanonical Wnt as a prognostic marker in prostate cancer: "you can't always get what you Wnt".
Fisher RR; Pleskow HM; Bedingfield K; Miyamoto DT
Expert Rev Mol Diagn; 2020 Feb; 20(2):245-254. PubMed ID: 31814454
[No Abstract] [Full Text] [Related]
[Next] [New Search]
